GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » E10

Aspira Womens Health (FRA:CUL) E10 : €-5.14 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aspira Womens Health's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.359. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-5.14 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 9.40% per year. During the past 5 years, the average E10 Growth Rate was 16.80% per year. During the past 10 years, the average E10 Growth Rate was 27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Aspira Womens Health was 56.40% per year. The lowest was 9.40% per year. And the median was 23.10% per year.

As of today (2024-05-25), Aspira Womens Health's current stock price is €2.02. Aspira Womens Health's E10 for the quarter that ended in Mar. 2024 was €-5.14. Aspira Womens Health's Shiller PE Ratio of today is .


Aspira Womens Health E10 Historical Data

The historical data trend for Aspira Womens Health's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health E10 Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.62 -5.64 -5.46 -5.61 -5.64

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.01 -7.23 -4.39 -5.64 -5.14

Competitive Comparison of Aspira Womens Health's E10

For the Diagnostics & Research subindustry, Aspira Womens Health's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Shiller PE Ratio falls into.



Aspira Womens Health E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aspira Womens Health's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.359/131.7762*131.7762
=-0.359

Current CPI (Mar. 2024) = 131.7762.

Aspira Womens Health Quarterly Data

per share eps CPI Adj_EPS
201406 -1.656 100.560 -2.170
201409 -1.862 100.428 -2.443
201412 -1.338 99.070 -1.780
201503 -1.386 99.621 -1.833
201506 -1.470 100.684 -1.924
201509 -1.336 100.392 -1.754
201512 -1.377 99.792 -1.818
201603 -1.212 100.470 -1.590
201606 -0.935 101.688 -1.212
201609 -0.936 101.861 -1.211
201612 -0.711 101.863 -0.920
201703 -0.701 102.862 -0.898
201706 -0.534 103.349 -0.681
201709 -0.755 104.136 -0.955
201712 -0.634 104.011 -0.803
201803 -0.608 105.290 -0.761
201806 -0.514 106.317 -0.637
201809 -0.514 106.507 -0.636
201812 -0.527 105.998 -0.655
201903 -0.664 107.251 -0.816
201906 -0.797 108.070 -0.972
201909 -0.545 108.329 -0.663
201912 -0.405 108.420 -0.492
202003 -0.543 108.902 -0.657
202006 -0.533 108.767 -0.646
202009 -0.509 109.815 -0.611
202012 -7.151 109.897 -8.575
202103 -0.630 111.754 -0.743
202106 -0.747 114.631 -0.859
202109 -1.148 115.734 -1.307
202112 -1.124 117.630 -1.259
202203 -1.126 121.301 -1.223
202206 -1.041 125.017 -1.097
202209 -1.010 125.227 -1.063
202212 -0.566 125.222 -0.596
202303 -0.738 127.348 -0.764
202306 -0.258 128.729 -0.264
202309 -0.450 129.860 -0.457
202312 -0.275 129.419 -0.280
202403 -0.359 131.776 -0.359

Add all the adjusted EPS together and divide 10 will get our e10.


Aspira Womens Health  (FRA:CUL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aspira Womens Health E10 Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines